$-0.02
(Market cap
$47 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-6 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2.6
-
Debt to Equity
0.6
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
60,748,600
10 Years Aggregate
CFO
€-293.44 Mln
EBITDA
€-322.41 Mln
Net Profit
€-315.67 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Erytech Pharma S.A. - ADR
| 106.5 | -17.6 | -22.1 | -34.5 | -56.0 | -42.6 | -- |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|
|
Erytech Pharma S.A. - ADR
| -86.0 | -74.5 | 25.2 | 8.9 | -69.0 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Erytech Pharma S.A. - ADR
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of... second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-"-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France. Read more
-
CEO & Director
Mr. Gil Beyen BVBA
-
CEO & Director
Mr. Gil Beyen BVBA
-
Headquarters
Lyon
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Erytech Pharma S.A. - ADR
What is the current share price of Erytech Pharma SA - ADR Today?
The share price of Erytech Pharma SA - ADR is $0.68 (NASDAQ) as of 26-Jul-2023 09:30 EDT. Erytech Pharma SA - ADR has given a return of -56% in the last 3 years.
What is the current PB & PE ratio of Erytech Pharma SA - ADR?
Since, TTM earnings of Erytech Pharma SA - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
What is the 52 Week High and Low of Erytech Pharma SA - ADR?
The 52-week high and low of Erytech Pharma SA - ADR are Rs -- and Rs -- as of 13-Jun-2026.
What is the market cap of Erytech Pharma SA - ADR?
Erytech Pharma SA - ADR has a market capitalisation of $ 47 Mln as on 26-Jul-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Erytech Pharma SA - ADR?
Before investing in Erytech Pharma SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.